Sakar Healthcare Limited has informed the Exchange regarding Outcome of Board Meeting held on May 15, 2025.
SAKAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sakar Healthcare's Board approved its audited results for the year ended 31 March 2025. Revenue from operations grew about 16% to Rs. 17,758 lakh (from Rs. 15,335 lakh a year ago). Profit after tax jumped nearly 50% to Rs. 1,750 lakh (vs Rs. 1,167 lakh), with EPS rising to Rs. 7.97 from Rs. 5.64. Operating cash flow strengthened to Rs. 3,403 lakh versus Rs. 2,447 lakh last year, though cash and equivalents on the balance sheet dropped to just Rs. 10 lakh. Statutory auditors J.S. Shah & Co. issued an unmodified (clean) opinion on both standalone and consolidated results.
Strong earnings growth and clean audit opinion are positive for shareholders. The near-zero cash balance despite healthy operating cash flow is a point to watch, as most cash is being absorbed into capital expenditure and working capital. Overall, results support a constructive view on the stock.